← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $611B	3,755	+23	+0.6%	$300B
2	2 Merck MRK $365B	3,257	+76	+2%	$224B
3	3 AbbVie ABBV $506B	3,079	-62	-2%	$165B
4	4 Pfizer PFE $170B	3,044	-61	-2%	$145B
5	5 Bristol-Myers Squibb BMY $125B	2,482	-60	-2%	$102B
6	6 Amgen AMGN $238B	2,391	-44	-2%	$90.1B
7	7 Gilead Sciences GILD $198B	1,702	-35	-2%	$80.6B
8	8 Novartis NVS $287B	1,201	+21	+2%	$14.9B
9	9 Regeneron Pharmaceuticals REGN $82.6B	1,164	-27	-2%	$66.2B
10	10 AstraZeneca AZN $259B	1,091	+36	+3%	$35.4B
11	11 GSK GSK $98.6B	827	+19	+2%	$9.91B
12	12 DELISTED Exact Sciences EXAS	652	+68	+12%	$15.3B
13	SGEN 13 DELISTED Seagen Inc. Common Stock SGEN	594	+19	+3%	$32B
14	14 Incyte INCY $23.1B	527	-24	-4%	$13.1B
15	15 Jazz Pharmaceuticals JAZZ $13.9B	471	0	0%	$7.05B
16	16 Lantheus LNTH $6.53B	431	+44	+11%	$5.71B
17	17 Exelixis EXEL $15.5B	379	+14	+4%	$5.22B
18	18 Halozyme HALO $13.8B	370	-16	-4%	$4.45B
19	19 Natera NTRA $58.1B	317	-10	-3%	$5.3B
20	20 Takeda Pharmaceutical TAK $62.7B	310	+10	+3%	$1.32B
21	21 Guardant Health GH $22.3B	299	+20	+7%	$3.95B
22	22 Qiagen QGEN $9.56B	283	-4	-1%	$6.14B
23	23 DELISTED Immunogen Inc IMGN	266	+76	+40%	$4.24B
24	24 NeoGenomics NEO $2.21B	266	+10	+4%	$1.89B
25	25 BioNTech BNTX $22.7B	252	-29	-10%	$4.05B